Publicacións en colaboración con investigadores/as de Hospital Universitario de Cruces (18)

2024

  1. A comprehensive, predictive mortality score for patients with bloodstream infections (PROBAC): a prospective, multicentre cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 8, pp. 1794-1800

  2. Association of microbiological factors with mortality in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study

    Clinical Microbiology and Infection, Vol. 30, Núm. 8, pp. 1035-1041

  3. Differences in clinical outcomes of bloodstream infections caused by Klebsiella aerogenes, Klebsiella pneumoniae and Enterobacter cloacae: a multicentre cohort study

    Annals of Clinical Microbiology and Antimicrobials, Vol. 23, Núm. 1

  4. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

  5. Mortality impact of further delays in active targeted antibiotic therapy in bacteraemic patients that did not receive initial active empiric treatment: Results from the prospective, multicentre cohort PROBAC

    International Journal of Infectious Diseases, Vol. 145

  6. Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: a multicentre cross-sectional study

    The Lancet Microbe, Vol. 5, Núm. 4, pp. e390-e399

2023

  1. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial

    Nature Medicine, Vol. 29, Núm. 10, pp. 2518-2525

2022

  1. Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project

    Microbiology spectrum, Vol. 10, Núm. 4, pp. e0005122

  2. Risk of cardiac device-related infection in patients with late-onset bloodstream infection. Analysis on a National Cohort

    Journal of Infection, Vol. 85, Núm. 2, pp. 123-129

  3. Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial)

    PLoS ONE, Vol. 17, Núm. 12 December

2021

  1. Impact of the COVID-19 pandemic on the diagnosis, management and prognosis of infective endocarditis

    Clinical Microbiology and Infection

  2. Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study)

    International Journal of Antimicrobial Agents, Vol. 58, Núm. 1

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Prediction of recurrent clostridium difficile infection at the bedside: the GEIH-CDI score

    International Journal of Antimicrobial Agents, Vol. 51, Núm. 3, pp. 393-398

2016

  1. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1